These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 26916712)

  • 21. Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen.
    Brumme ZL; Henrick BM; Brumme CJ; Hogg RS; Montaner JS; Harrigan PR
    Antivir Ther; 2005; 10(7):849-53. PubMed ID: 16312181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care.
    Weintrob AC; Grandits GA; Agan BK; Ganesan A; Landrum ML; Crum-Cianflone NF; Johnson EN; Ordóñez CE; Wortmann GW; Marconi VC;
    J Acquir Immune Defic Syndr; 2009 Dec; 52(5):574-80. PubMed ID: 19755913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective study of highly active antiretroviral therapy in Indian human immunodeficiency virus positive patients.
    Rajesh R; Vidyasagar S; Varma DM; Naik A; Hegde BM; Guddattu V; Kamath A
    Int J Risk Saf Med; 2013 Jan; 25(1):53-65. PubMed ID: 23442298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study.
    Conen A; Fehr J; Glass TR; Furrer H; Weber R; Vernazza P; Hirschel B; Cavassini M; Bernasconi E; Bucher HC; Battegay M;
    Antivir Ther; 2009; 14(3):349-57. PubMed ID: 19474469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alcohol consumption and lipodystrophy in HIV-infected adults with alcohol problems.
    Cheng DM; Libman H; Bridden C; Saitz R; Samet JH
    Alcohol; 2009 Feb; 43(1):65-71. PubMed ID: 19185212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune reconstitution and predictors of virologic failure in adolescents infected through risk behaviors and initiating HAART: week 60 results from the PACTG 381 cohort.
    Rudy BJ; Lindsey JC; Flynn PM; Bosch RJ; Wilson CM; Hughes ME; Douglas SD;
    AIDS Res Hum Retroviruses; 2006 Mar; 22(3):213-21. PubMed ID: 16545007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Joint longitudinal data analysis in detecting determinants of CD4 cell count change and adherence to highly active antiretroviral therapy at Felege Hiwot Teaching and Specialized Hospital, North-west Ethiopia (Amhara Region).
    Seyoum A; Ndlovu P; Temesgen Z
    AIDS Res Ther; 2017 Mar; 14(1):14. PubMed ID: 28302125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alcohol consumption and HIV disease progression: are they related?
    Samet JH; Horton NJ; Traphagen ET; Lyon SM; Freedberg KA
    Alcohol Clin Exp Res; 2003 May; 27(5):862-7. PubMed ID: 12766632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.
    Frange P; Briand N; Avettand-fenoel V; Veber F; Moshous D; Mahlaoui N; Rouzioux C; Blanche S; Chaix ML
    Pediatr Infect Dis J; 2011 Aug; 30(8):684-8. PubMed ID: 21427626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of alcohol consumption and HIV surrogate markers in participants of the swiss HIV cohort study.
    Conen A; Wang Q; Glass TR; Fux CA; Thurnheer MC; Orasch C; Calmy A; Bernasconi E; Vernazza P; Weber R; Bucher HC; Battegay M; Fehr J
    J Acquir Immune Defic Syndr; 2013 Dec; 64(5):472-8. PubMed ID: 23892243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD4 T cell count reconstitution in HIV controllers after highly active antiretroviral therapy.
    Okulicz JF; Grandits GA; Weintrob AC; Landrum ML; Ganesan A; Crum-Cianflone NF; Agan BK; Marconi VC
    Clin Infect Dis; 2010 Apr; 50(8):1187-91. PubMed ID: 20218878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Highly active antiretroviral therapy discontinuation time is associated with therapeutic failure among human immunodeficiency virus (HIV)-infected immigrant adults: A cohort study from a Peruvian referral hospital during the Venezuelan exodus.
    Rebolledo-Ponietsky K; Al-Kassab-Córdova A; Lucchetti-Rodríguez A; Cabieses B; Rodriguez-Morales AJ; Mezones-Holguín E
    Trop Med Int Health; 2023 Aug; 28(8):641-652. PubMed ID: 37414409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Virologic suppression among HIV-infected US Air Force members in a highly-structured programme with free access to care.
    Matthews PE; Le T; Delmar J; Okulicz JF
    Int J STD AIDS; 2015 Nov; 26(13):951-9. PubMed ID: 25505041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors associated with poor immunologic response to virologic suppression by highly active antiretroviral therapy in HIV-infected women.
    Vaamonde CM; Hoover DR; Anastos K; Tan T; Shi Q; Gao W; Kovacs A; Cohen M; DeHovitz J; Glesby MJ
    AIDS Res Hum Retroviruses; 2006 Mar; 22(3):222-31. PubMed ID: 16545008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection.
    Powles T; Robinson D; Stebbing J; Shamash J; Nelson M; Gazzard B; Mandelia S; Møller H; Bower M
    J Clin Oncol; 2009 Feb; 27(6):884-90. PubMed ID: 19114688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
    Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
    Jaspan HB; Berrisford AE; Boulle AM
    Pediatr Infect Dis J; 2008 Nov; 27(11):993-8. PubMed ID: 18818556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship of chronic hepatitis C infection to rates of AIDS-defining illnesses in a Canadian cohort of HIV seropositive individuals receiving highly active antiretroviral therapy.
    Raboud J; Anema A; Su D; Klein MB; Zakaryan A; Swan T; Palmer A; Hosein S; Loutfy MR; Machouf N; Montaner JS; Rourke SB; Tsoukas C; Hogg RS; Cooper C;
    HIV Clin Trials; 2012; 13(2):90-102. PubMed ID: 22510356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
    Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.